Status:
COMPLETED
Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect
Lead Sponsor:
Santen Pharmaceutical Co., Ltd.
Conditions:
Persistent Corneal Epithelial Defect
Eligibility:
All Genders
12+ years
Phase:
PHASE2
Brief Summary
Safety and efficacy of DE-105 ophthalmic solution in patients with persistent corneal epithelial defect will be evaluated. Dose-dependent efficacy will be evaluated as well.
Eligibility Criteria
Inclusion
- Has corneal epithelial defect and decreased corneal sensitivity.
- Has undergone continuous treatment for corneal epithelial defect for 1 week or longer.
Exclusion
- Presence of disease such as active ocular infection, or abnormal lid closure.
- History or presence of chemical burn, Stevens - Johnson Syndrome, etc.
- History of corneal transplantation, LASIK, or hematopoietic stem cell transplantation.
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00988494
Start Date
September 1 2009
Last Update
November 22 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Santen study sites
Osaka, Japan